ISRCTN42727091进行中（未招募）2 期
Dissecting the Contribution of glucocorticoid metabolism in Mild Autonomous Cortisol Secretion: a randomised controlled trial of the 11ß-HSD1 inhibitor SPI-62
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant is willing and able to give informed consent for participation in the trial
- •2. Aged 18 years or above
- •3. 09.00 h serum cortisol >51 nmol/L after overnight dexamethasone (1 mg) within the last 6 months performed in the absence (for at least 4 weeks prior to testing) of concomitant estrogen-containing medication.
- •4. Adrenal adenoma(s) that has (have) not been surgically removed, and with benign characteristics on cross-sectional imaging.
- •5. Body mass index 18 to 45 kg/m2
- •6. Stable dose of current regular antihypertensive and/or glucose-lowering medication for at least 12 weeks prior to trial entry.
- •7. Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they and their partner use effective contraception during the trial and for 90 days thereafter.
- •8. In the Investigator’s opinion, the participant is able and willing to comply with all trial requirements.
- •9. Participant is willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial
排除标准
- •1. Female participant is pregnant, lactating, or planning pregnancy during the course of the trial
- •2. Scheduled elective surgery or other procedures requiring general anaesthesia are required during the course of the trial
- •3. Participants with a life expectancy of less than 6 months
- •4. A diagnosis of idiopathic thrombocytopenic purpura or any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial
- •5. A clinical phenotype consistent with classical Cushing’s syndrome (e.g. thin skin, easy bruising, proximal myopathy)
- •6. Evidence from medical records of elevated aldosterone/renin ratio (above local reference range) on blood sampling
- •7. Renal impairment indicated by eGFR <60 ml/min/1.73 m², calculated using an appropriate and validated equation
- •8. Participants with a diagnosis of liver cirrhosis or liver function test (LFT) elevations that exceed 1.5 x the upper limit of normal at screening and require further clinical investigation: LFT pattern consistent with Gilbert’s syndrome is allowed
- •9. Recent (< 1 year) myocardial infarction or stroke, orthostatic or vasovagal syncope
- •10. QT interval corrected (QTc) interval >500 ms, uncorrected QT interval >600 ms, or evidence of significant, life-threatening arrhythmia or bradycardia (heart rate <45 bpm) according to electrocardiogram (ECG)
- •11. Anaemia, defined as haemoglobin =110 g/L (female) and =130 g/L (male)
- •12. Untreated hypothyroidism
- •13. Taking a prohibited medication or exposure to a prohibited medication (section 10.6)
- •14. Current evidence or significant past history of alcohol misuse disorder (> 35 units per week female and >50 units per week male, or other indicators of possible alcohol misuse) in the opinion of the Investigator
- •15. Uncontrolled hypertension (>160/100 mmHg)
- •16. Type 1 diabetes or Type 2 diabetes requiring medication (with the exception of metformin monotherapy)
- •17. Recent (within the last 3 months) or planned night-shift work during the duration of the study
- •18. Contraindication to any of the study treatments or known or suspected hypersensitivity ?to the investigational product, compounds of the same class, other study treatments or any excipients
- •19. Participation in an interventional study in which involvement was completed less than 12 weeks before recruitment into the current study
- •20. Administration of any vaccine within 4 weeks prior to randomization or planned during the trial
- •21. SARS-CoV-2 infection within 4 weeks, or hospitalization for COVID-19 disease within 6 months, prior to randomization
- •22. Any major surgery within 1 month prior to randomization or planned during the trial
研究者
相似试验
已完成
不适用
Treatment Side Effects and Changes to Physical Function in Newly-Diagnosed Polymyalgia RheumaticaPolymyalgia RheumaticaSarcopeniaInflammatory and Immune System - Autoimmune diseasesMusculoskeletal - Other muscular and skeletal disordersACTRN12618001522202Austin Health68
暂停
不适用
Acute and chronic effects of glucocorticoids on carbohydrate metabolism in subjects with inflammatory rheumatologic disease.inflammatory rheumatologic diseaseMetabolic and Endocrine - Other metabolic disordersCardiovascular - Other cardiovascular diseasesInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12610000409077Dr Morton Burt24
进行中（未招募）
1 期
A study of markers of glucocorticoid effectsAdrenal insufficiency e.g. Addison´s diseaseEUCTR2016-004078-16-SESahlgrenska University Hospital, Gothenburg30
已完成
不适用
Study on the glucocorticoid-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trialAdult Still's disease or systemic juvenile idiopathic arthritisJPRN-UMIN000001250Division of Rheumatology & Clinical Immunology, Jichi Medical University10
招募中
2 期
Impact of short-term low dose glucocorticoids on protein metabolismHealthy volunteersMetabolic and Endocrine - Normal metabolism and endocrine development and functionACTRN12605000443695St Vincent's Hospital8